TIL Company Profile and Key Details

TIL has shown weak momentum, losing -0.98% over the past week and -62.9% over the past quarter, though year-to-date performance is down -35.64%. Short-term trend indicators are bullishly aligned (SMA20 11.26%, SMA50 3.91%, SMA200 -52.04%). The stock’s 14-day RSI is 57.91 (neutral), while the ATR of 0.58 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -78.99% below its high and over 58.55% above its low. Average 10-day trading volume of 9.01 thousand shares is below the 3-month average of 20.30 thousand, indicating normal recent market interest.

Instil Bio, Inc. has 6.75 million shares outstanding. The public float is 3.31 million shares, elevated short interest at 23.74% of float. This equals 950.37 thousand shares. The short ratio is 7.11 days. Institutional investors hold 66.45% of the float. Insiders own 6.56%. Crouch Bronson holds 37.98 million shares, Curative Ventures V LLC has 37.98 million shares and Nielsen Jack has 12.49 million shares.

Instil Bio, Inc. generated EPS of -$11.39 over the past year. Five-year average earnings growth is -62.1%. The latest quarter delivered EPS of -$0.62. The next quarter is forecast at -$2.04. Next year's EPS is expected at $47.98. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 3 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $125.00 to $125.00. The high target offers 1566.67% upside. The low target suggests 1566.67% downside. The mean target is $125.00. This offers 1566.67% upside. Instil Bio, Inc. earnings surprise history is a consistent trend of beating forecasts. The quarter that ended May 15, 2026, missed forecasts by 0.0%. The prior quarter beat by 0.0%. Over the last six quarters, Apple has recorded several small beats. These include 113.86% in May 13, 2025.

Instil Bio, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $1.00. This means the shares are trading above this model’s fair value.

Instil Bio, Inc. (NASDAQ:TIL) closed at $7.50 USD, gaining $0.24 (3.31%) from the previous close of $7.26. The stock is currently mid-range between its 52-week high and low $5.67 and $33.83. With a market capitalization of about $50.86 million, Instil Bio, Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~1.91). Key stats such as the average daily volume over the past year has been around 20.12 thousand shares, volume is running light vs its 52-week average. Headquartered in Dallas, TX, Instil Bio, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Bronson Crouch, the company employs approximately 17 people and listed since March 19, 2021. Instil Bio, Inc. operates as a clinical-stage biopharmaceutical firm, concentrating its efforts on devising novel therapeutic options for individuals battling cancer.

Instil Bio, Inc. trades at a P/E ratio of -1.02, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 0.44 suggesting the stock is closer to book value. The P/FCF stands at -1.45, also above market averages.

Instil Bio, Inc. (NASDAQ:TIL) shares are down -35.64% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Instil Bio, Inc. trading at a premium to the broader market with a P/E of -1.02. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $62.46, suggesting 732.8% upside. Our AI forecast model points to short-term weakness (-3.07% over two weeks), a medium-term fall (-13.6% over three months), and a longer-term loss (-68.67% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Instil Bio, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -3.07%, with price expected at $7.27 by August 19, 2026, within a range of $7.02 to $7.55 3-Month Outlook: Projected fall of -13.6%, reaching $6.48 by November 03, 2026, with a range of $4.90 to $7.36. 1-Year Outlook: Projected loss of -68.67%, with price at $2.35 by August 05, 2027, within a range of $0.00 to $0.00.